Is Syntara (ASX:SNT) In A Good Position To Deliver On Growth Plans?
May 10
Have your own idea? Try our Stock Screener
Australian (ASX) Pharma Industry Analysis
UpdatedMay 11, 2025
DataAggregated Company Financials
Companies28
- 7D1.9%
- 3M-9.2%
- 1Y-15.4%
- YTD-7.6%
Over the last 7 days, the Pharma industry has risen 1.9%, driven by gains from Neuren Pharmaceuticals of 6.8%. Meanwhile, Clarity Pharmaceuticals actually underperformed within the industry, shrinking 6.5% in the last week. However, the industry is down 15% over the past year. Earnings are forecast to grow by 49% annually.
Industry Valuation and Performance
Has the Australian Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 11 May 2025 | AU$4.9b | AU$1.0b | -AU$238,266,485.00 | 18.2x | -20.7x | 4.7x |
| Tue, 08 Apr 2025 | AU$3.7b | AU$1.0b | -AU$238,266,485.00 | 16.7x | -15.6x | 3.6x |
| Thu, 06 Mar 2025 | AU$5.0b | AU$1.1b | -AU$305,755,525.00 | 18.2x | -16.4x | 4.7x |
| Sat, 01 Feb 2025 | AU$5.4b | AU$1.0b | -AU$378,981,112.00 | 12x | -14.2x | 5.3x |
| Mon, 30 Dec 2024 | AU$5.3b | AU$1.0b | -AU$378,981,112.00 | 12.2x | -13.9x | 5.2x |
| Wed, 27 Nov 2024 | AU$5.7b | AU$1.0b | -AU$377,703,112.00 | 12.9x | -15.1x | 5.6x |
| Fri, 25 Oct 2024 | AU$6.0b | AU$1.0b | -AU$377,703,112.00 | 13.3x | -15.8x | 5.9x |
| Sun, 22 Sep 2024 | AU$6.9b | AU$1.0b | -AU$370,332,028.00 | 13.3x | -18.5x | 6.8x |
| Tue, 20 Aug 2024 | AU$6.2b | AU$995.3m | -AU$387,920,108.00 | 10.5x | -15.9x | 6.2x |
| Thu, 18 Jul 2024 | AU$7.0b | AU$995.3m | -AU$387,920,108.00 | 11.5x | -18x | 7x |
| Sat, 15 Jun 2024 | AU$6.4b | AU$1.2b | -AU$379,935,217.00 | 14.9x | -17x | 5.3x |
| Mon, 13 May 2024 | AU$5.9b | AU$1.2b | -AU$374,923,684.00 | 12.6x | -15.9x | 4.9x |
| Wed, 10 Apr 2024 | AU$5.8b | AU$1.2b | -AU$374,923,684.00 | 14.3x | -15.6x | 4.8x |
| Fri, 08 Mar 2024 | AU$5.5b | AU$1.2b | -AU$397,868,496.00 | 13.6x | -13.7x | 4.5x |
| Sun, 04 Feb 2024 | AU$5.6b | AU$896.3m | -AU$589,604,392.00 | 20.9x | -9.6x | 6.3x |
| Tue, 02 Jan 2024 | AU$5.8b | AU$896.3m | -AU$589,604,392.00 | 21.4x | -9.9x | 6.5x |
| Thu, 30 Nov 2023 | AU$4.2b | AU$893.0m | -AU$595,020,018.00 | 18.1x | -7x | 4.7x |
| Sat, 28 Oct 2023 | AU$3.4b | AU$900.3m | -AU$587,952,018.00 | 18.5x | -5.9x | 3.8x |
| Mon, 25 Sep 2023 | AU$3.5b | AU$900.3m | -AU$587,952,018.00 | 19x | -6x | 3.9x |
| Wed, 23 Aug 2023 | AU$4.1b | AU$1.0b | -AU$640,867,807.00 | 19.1x | -6.4x | 4.1x |
| Fri, 21 Jul 2023 | AU$4.5b | AU$999.0m | -AU$624,794,303.00 | 24.2x | -7.2x | 4.5x |
| Sun, 18 Jun 2023 | AU$3.9b | AU$999.0m | -AU$624,794,303.00 | 19.1x | -6.3x | 3.9x |
| Tue, 16 May 2023 | AU$4.1b | AU$993.2m | -AU$640,306,659.00 | 18.6x | -6.5x | 4.2x |
| Thu, 13 Apr 2023 | AU$4.1b | AU$993.2m | -AU$641,969,868.00 | 18.1x | -6.4x | 4.1x |
| Sat, 11 Mar 2023 | AU$3.6b | AU$995.9m | -AU$648,651,745.00 | 21.8x | -5.5x | 3.6x |
| Mon, 06 Feb 2023 | AU$3.7b | AU$951.8m | -AU$584,038,383.00 | 17x | -6.4x | 3.9x |
| Wed, 04 Jan 2023 | AU$3.9b | AU$948.3m | -AU$544,428,006.00 | 13.2x | -7.2x | 4.1x |
| Fri, 02 Dec 2022 | AU$4.1b | AU$948.3m | -AU$544,428,005.00 | 13.3x | -7.6x | 4.4x |
| Sun, 30 Oct 2022 | AU$4.2b | AU$946.2m | -AU$548,400,005.00 | 11.7x | -7.7x | 4.5x |
| Tue, 27 Sep 2022 | AU$4.0b | AU$943.4m | -AU$537,515,354.00 | 12.3x | -7.4x | 4.2x |
| Thu, 25 Aug 2022 | AU$4.1b | AU$840.9m | -AU$340,365,465.00 | 13.9x | -12x | 4.8x |
| Sat, 23 Jul 2022 | AU$3.7b | AU$818.2m | -AU$353,932,589.00 | 15.9x | -10.3x | 4.5x |
| Mon, 20 Jun 2022 | AU$3.2b | AU$818.2m | -AU$353,932,589.00 | 12.8x | -9.1x | 3.9x |
| Wed, 18 May 2022 | AU$4.1b | AU$818.3m | -AU$353,932,589.00 | 13.7x | -11.6x | 5x |
Price to Earnings Ratio
-11.6x
Current Industry PE
- Investors are relatively neutral on the Australian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 4.9x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
- Revenues for these companies have grown 8.4% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Trends
Which industries have driven the changes within the Australian Healthcare industry?
| AU Market | 0.058% | |
| Healthcare | -3.19% | |
| Pharma | 1.89% | |
| Pharma | 1.89% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| NEU Neuren Pharmaceuticals | AU$13.29 | 6.8% +AU$106.4m | -30.4% | PE11.7x | |
| BOT Botanix Pharmaceuticals | AU$0.47 | 2.2% +AU$19.5m | 69.1% | PS439.1x | |
| SNT Syntara | AU$0.067 | 13.6% +AU$13.0m | 272.2% | PS13.3x | |
| MYX Mayne Pharma Group | AU$7.12 | 1.7% +AU$9.7m | 1.6% | PS1.4x | |
| TYP Tryptamine Therapeutics | AU$0.034 | 9.7% +AU$4.3m | n/a | PS36.9x |
